Stock Movers: Deere & Co., Moderna, Strategy (Podcast)

Deere shares rose premarket after it narrowed its fiscal-year net income outlook to $4.75B-$5.0B versus the prior range of $4.5B-$5.0B, citing a stabilization in agriculture and a more pronounced rebound next year. Moderna shares fell despite earlier strength after late-stage trial data showed its personalized cancer vaccine plus Merck’s Keytruda cut melanoma recurrence and met secondary goals on preventing spread. Separately, crypto-linked stocks (including Strategy/MSTR) climbed premarket as Bitcoin’s rally triggered record short liquidations and Trump met with crypto executives.

Analysis

DE is the cleaner fundamental signal in the set: ag machinery is one of the few industrial end-markets where a mild improvement in farm economics can translate into a disproportionate order rebound because fleets are aging and dealer inventories have already normalized. The market should treat this as a 1-3 quarter lead indicator, not an immediate earnings step-up; the bigger upside is into next spring’s order book if commodity prices and farm income stay stable. The main risk is that a better headline outlook gets pulled forward into the stock, leaving little room if crop prices roll over or replacement demand proves too elastic.

MRNA’s data read-through is more about platform validation than near-term revenue. The commercial prize likely sits with MRK, because any oncology combination that extends Keytruda’s lifecycle has far more certainty of being monetized than a stand-alone personalized vaccine franchise, which still faces reimbursement, manufacturing, and adoption friction over 6-18 months. The consensus may be overpricing the idea that one successful trial automatically creates a large, durable new category; that usually requires multiple indications and cleaner operational scalability.

MSTR is still a positioning trade first and a fundamentals trade second. The squeeze can persist for days to weeks while short covering and momentum chase BTC higher, but the equity remains vulnerable to a sharp reversal if crypto volatility compresses, funding rates reset, or BTC pauses long enough for leverage to matter. For investors who want BTC beta, MSTR remains the more fragile vehicle because the balance sheet and equity dilution can cut both ways in a drawdown.

Key Decisions for Investors

• Long DE vs short CAT or XLI for the next 1-3 months: DE has cleaner leverage to an ag capex inflection, while CAT is less sensitive to that specific rebound. Falsify on weaker-than-expected next dealer/order commentary or a crop-price rollover.
• Buy DE on pullbacks rather than chasing the gap; use a 3-6 month horizon for the order-cycle inflection. Risk/reward improves if the stock gives back most of the premarket move before the next crop-income data point.
• Long MRK / short MRNA as a relative-value expression over 1-3 months: MRK gets lifecycle extension optionality with less binary commercialization risk, while MRNA still needs to prove repeatable monetization. Falsify if MRNA secures clear partnership economics or faster regulatory milestones than expected.
• Avoid fresh MSTR longs after the squeeze; if you need crypto exposure, prefer BTC proxy names or spot-linked exposure over the next 1-4 weeks. MSTR is the highest beta to a momentum reversal and the first to give back gains if BTC stalls.
• If trading MSTR, consider a small tactical call spread only on dips with a hard risk cap; do not hold outright into a volatility fade. Exit if BTC loses momentum or short-interest data normalizes, as the squeeze dynamic can unwind quickly.